Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Series B

ImCheck imports $53m in series B cash
Pfizer Ventures led the immuno-oncology drug developer's latest round, which was spun out of Institut Paoli-Calmettes with the help of Satt Sud-Est and Inserm Transfert.
Heartseed to grow with series B funding
JMDC, Gene Techno Science, Astellas Venture Management and Nissay Capital have contributed to a $25.8m round for Keio University's heart failure treatment developer.
Azeria erects $42.2m series B
Azeria Therapeutics has picked up Syncona as an investor as it looks to bring its therapy for receptor-positive luminal breast cancer into the clinic.
Tissium grafts $42.8m
MIT-founded regenerative polymer developer Tissium will put the capital into clinical-stage development and toward regulatory clearance in multiple markets.
PMV pinpoints $62m investment
OUP returned for PMV's series C round which the company will use to cement its portfolio of small molecule treatments targeting cancerous p53 mutations.
Daily deal net: November 13, 2019
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
PureLifi lights up $18m
Returning investors Temasek and Scottish Investment Bank returned to back Edinburgh spinout PureLifi's series B round and bring the company's funding total to $29.5m.
HawkEye 360 takes series B to $85m
HawkEye 360 extended its series B round to at least $85m with a $15m contribution from family office Advance, which has also bought founding investor Allied Minds' stake.

Other News

eGenesis brings about $100m series B
Harvard's xenotransplantation technology developer eGenesis has raised a $100m in its series B round.
Acticor conjures up $24.7m series B
The Inserm spinout secured a $7.8m series B extension and boosted its portfolio with the acquisition of AVCare, a Satt Ouest Valorisation-allied business.
PierianDx clinches $27m series B
Genomics bioinformatics platform developer PierianDx, a Washington University in St Louis spinout, has raised fresh capital to advance its business strategy.
Tmunity teams with corporates to raise $75m
University of Pennsylvania returned for a series B round that boosted its immunotherapy spinout's overall funding to $231m.
Sandbox VR plays with another $11m
Having already collected $68m in a series A round backed by Stanford University earlier this year, Sandbox VR has added $11m to its coffers thanks to a long list of celebrities.
Cyteir takes series B to $75.2m
Jackson Laboratory cancer drug spinout Cyteir Therapeutics extended its series B round thanks to investors including Osage University Partners and Novo Holdings.

Editor's Picks

Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Canvas paints $9m picture
Canvas Network, an online education platform developed by learning management software (LMS) provider Instructure which received $9.1m investment for the platform, has begun offering free and open online courses.
WRF finds its Resolve
In May 2010, Resolve raised $2m in the initial close of its A round before bringing in a corporate venturing unit later.
Imperial helps PsiOxus raise $34m
UK-listed investment fund Imperial Innovations joins GlaxoSmithKline's SR One, fund manager Invesco Perpetual and Lundbeckfond Ventures, backing the d cancer treatment company.
test reg

Login